NCT06114056View on ClinicalTrials.gov

A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

November 13, 2029

Study Completion Date

November 13, 2029

Conditions
Duchenne Muscular Dystrophy
Interventions
BIOLOGICAL

JWK007 Single intravenous infusion administration

"Six male children aged 5-10 years were enrolled in the study. The patients were divided into two different dose groups, and a 3+3 dose escalation design was used, the low dose was 1.0×1014vg/kg, and the high dose was 2.0×1014vg/kg. Only one intravenous infusion of JWK007 was administered to each patient."

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT06114056 - A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD) | Biotech Hunter | Biotech Hunter